CEL-SCI Corp Total Liabilities
CEL-SCI Corp total liabilities. Based on the latest financial reports, CEL-SCI Corp (CVM) has total liabilities worth $11.76 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check CEL-SCI Corp liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of CEL-SCI Corp (1986–2025)
Total liabilities of CEL-SCI Corp from 1986 to 2025. This chart illustrates how CEL-SCI Corp's total liabilities have evolved over time, based on quarterly financial data.
CEL-SCI Corp Competitors by Total Liabilities
The table below lists competitors of CEL-SCI Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jaycorp Bhd
KLSE:7152
|
Malaysia | RM54.28 Million |
|
Field Solutions Holdings Ltd
AU:FSG
|
Australia | AU$48.22 Million |
|
Nanalysis Scientific Corp
V:NSCI
|
Canada | CA$22.05 Million |
|
Lithium Plus Minerals Ltd
AU:LPM
|
Australia | AU$369.68K |
|
CBL International Limited Ordinary Shares
NASDAQ:BANL
|
USA | $39.56 Million |
|
Merchants Trust PLC
LSE:MRCH
|
UK | GBX119.44 Million |
|
LOOP INDUSTRIES DL-001
F:3L9
|
Germany | €18.72 Million |
|
AIR INDUSTRIES GR.DL-001
F:YH1
|
Germany | €39.13 Million |
Liability Composition Analysis (1986–2025)
This chart breaks down CEL-SCI Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see CEL-SCI Corp asset portfolio.
Liquidity & Leverage Metrics
CEL-SCI Corp Total Liabilities Ratios Explained
CEL-SCI Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 1.25 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.51 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CEL-SCI Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CEL-SCI Corp (1986–2025)
The table below shows the annual total liabilities of CEL-SCI Corp from 1986 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-09-30 | $12.20 Million | -13.64% |
| 2024-09-30 | $14.12 Million | -18.42% |
| 2023-09-30 | $17.31 Million | -5.70% |
| 2022-09-30 | $18.36 Million | -5.04% |
| 2021-09-30 | $19.34 Million | -7.08% |
| 2020-09-30 | $20.81 Million | -7.47% |
| 2019-09-30 | $22.49 Million | -23.99% |
| 2018-09-30 | $29.59 Million | +12.66% |
| 2017-09-30 | $26.26 Million | +109.18% |
| 2016-09-30 | $12.55 Million | -39.29% |
| 2015-09-30 | $20.68 Million | +135.32% |
| 2014-09-30 | $8.79 Million | +112.33% |
| 2013-09-30 | $4.14 Million | -54.22% |
| 2012-09-30 | $9.04 Million | -5.31% |
| 2011-09-30 | $9.55 Million | -4.06% |
| 2010-09-30 | $9.95 Million | -73.24% |
| 2009-09-30 | $37.19 Million | +866.49% |
| 2008-09-30 | $3.85 Million | -36.52% |
| 2007-09-30 | $6.06 Million | -42.74% |
| 2006-09-30 | $10.58 Million | +971.99% |
| 2005-09-30 | $987.31K | +357.13% |
| 2004-09-30 | $215.98K | -87.22% |
| 2003-09-30 | $1.69 Million | -37.61% |
| 2002-09-30 | $2.71 Million | +433.57% |
| 2001-09-30 | $507.73K | -40.09% |
| 2000-09-30 | $847.42K | +69.48% |
| 1999-09-30 | $500.00K | +25.00% |
| 1998-09-30 | $400.00K | -20.00% |
| 1997-09-30 | $500.00K | +66.67% |
| 1996-09-30 | $300.00K | -81.25% |
| 1995-09-30 | $1.60 Million | +14.29% |
| 1994-09-30 | $1.40 Million | +100.00% |
| 1993-09-30 | $700.00K | +40.00% |
| 1992-09-30 | $500.00K | -28.57% |
| 1991-09-30 | $700.00K | +40.00% |
| 1990-09-30 | $500.00K | 0.00% |
| 1989-09-30 | $500.00K | -28.57% |
| 1988-09-30 | $700.00K | +133.33% |
| 1987-09-30 | $300.00K | -25.00% |
| 1986-09-30 | $400.00K | -- |
About CEL-SCI Corp
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation S… Read more